Earnings ·
Sinovac Biotech Ltd. reported unaudited financial results for the first half of 2026 ending June 30, 2026
SVASinovac Biotech Ltd
Sinovac Biotech Ltd. reported unaudited financial results for the first half of 2026 ending June 30, 2026. Total sales increased 12.9% to $147.1 million from $130.3 million in the prior year period, driven by an 82.3% surge in overseas revenue to $66.5 million. The company posted a net loss attributable to common shareholders of $60.2 million, or $0.84 per share, compared to a $21.7 million loss, or $0.30 per share, in the prior year period. Gross profit margin expanded to 65.0% from 62.5%, while selling, general and administrative expenses decreased to $130.9 million due to efficiency improvements. Subsequent to the reporting period, Sinovac received NMPA marketing approval for its rabies vaccine (PVRV-SF) on August 4, 2026, and the NDA for its bivalent enterovirus vaccine was accepted for priority review. The company holds $998.5 million in cash and equivalents as of June 30, 2026. Sinovac Biotech Ltd. is a global biopharmaceutical company headquartered in China dedicated to the research, development, manufacturing, and supply of vaccines.